Author

K. Boelaert

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Assay:proteomics· 3 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:gene regulatory network inference· 1 Approach:statistical model· 1

Frequent Co-Authors

C. J. McCabe· 4 shared H. R. Nieto· 4 shared K. Brookes· 4 shared M. L. Read· 4 shared V. E. Smith· 4 shared A. Fletcher· 3 shared M. J. Campbell· 3 shared C. E. M. Thornton· 2 shared

Activity by Year

2019-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

C. J. McCabe

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Dual agonism of sodium iodide symporter function in vivo

K. Brookes, C. M. Thornton, L. Zha, J. Kim, B. Small, S. Manivannan, H. R. Nieto, H. Adcock, G. Bottegoni, L. R. Cox, V. Kannappan, W. Wang, C. M. Gorvin, S. Jhiang, M. D. Ringel, , C. J. McCabe

This study identifies Cu(DDC)2-alb as a dual agonist that enhances RAI uptake in thyroid cancer by stabilizing NIS and inducing thyroid transcription factors.

bioRxiv · Feb 27, 2024 · PreprintCancer Biology

Dissecting endocytic mechanisms reveals new molecular targets to enhance sodium iodide symporter activity with clinical relevance to radioiodide therapy

M. L. Read, K. Brookes, L. Zha, S. Manivannan, J. Kim, M. Kocbiyik, A. Fletcher, C. M. Gorvin, G. Firth, G. O. Fruhwirth, J. P. Nicola, S. Jhiang, M. D. Ringel, M. J. Campbell, K. Sunassee, , C. J. McCabe

This study identifies an acidic dipeptide in NIS that mediates AP2 binding, showing chloroquine enhances NIS membrane retention and RAI uptake in thyroid cancer.

bioRxiv · May 22, 2023 · PreprintCancer Biology

New mechanisms of radioiodide uptake revealed via a novel high throughput drug screening approach in thyroid cancer

M. L. Read, K. Brookes, C. E. M. Thornton, A. Fletcher, M. Alshahrani, R. Khan, H. R. Nieto, P. Borges de Souza, J. R. M. Webster, L. J. Alderwick, K. Boelaert, V. E. Smith, C. J. McCabe

This study identifies FDA-approved drugs that enhance radioiodide uptake through non-canonical NIS processing pathways, revealing new therapeutic strategies for thyroid cancer.

bioRxiv · Jul 21, 2020 · PreprintCancer Biology

Pharmacologically targeting a novel pathway of sodium iodide symporter trafficking to enhance radioiodine uptake

A. Fletcher, M. L. Read, C. E. M. Thornton, D. P. Larner, V. L. Poole, K. Brookes, H. R. Nieto, M. Alshahrani, R. J. Thompson, G. G. Lavery, M. J. Campbell, K. Boelaert, A. S. Turnell, V. E. Smith, C. J. McCabe

This study identifies ARF4 and VCP as regulators of NIS trafficking and shows FDA-approved VCP inhibitors enhance radioiodine uptake in thyroid cancer cells and mice.

bioRxiv · May 7, 2019 · PreprintCancer Biology